Endocrinology News

NATIONAL HARBOR, Md. — There is a need to identify patients with obstructive sleep apnea after a weight-loss drug was approved for treatment of the disorder in those with obesity, a speaker said.

A consensus statement published in Endocrine Practice examines how health care professionals should approach treating and screening people with tumors associated with multiple endocrine neoplasia type 1.

Individuals using e-cigarettes exclusively had a significantly elevated risk for COPD, whereas this was not found when assessing the risk for type 2 diabetes or heart failure, according to data published in Nicotine and Tobacco Research.

Higher BMI cutoffs are needed to diagnose overweight and obesity in male athletes, researchers reported in a study published in Nutrients.

The likelihood for antibody-mediated rejection in lung transplant recipients was heightened with vs. without GLP-1 receptor agonist use, whereas the odds for mortality dropped with use, according to a poster presentation.

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with particular benefit observed for those with severe obesity, a speaker reported.

Personal continuous glucose monitors are accurate at measuring glucose levels in most ranges for hospitalized patients with diabetes, researchers report in a study published in Diabetes Technology & Therapeutics.

NATIONAL HARBOR, Md. — GLP-1 receptor agonists are effective weight-loss medications, but they may also decrease muscle mass, raising concerns about the long-term effects of these drugs, according to Christos S. Katsanos, PhD.

NATIONAL HARBOR, Md. — In this video at Obesity Medicine 2025, Harold E. Bays, MD, FOMA, FTOS, FACC, FASPC, FNLA, discusses highlights from his talk on anti-obesity medications in the pipeline.